156 related articles for article (PubMed ID: 17881586)
1. A mouse model for nonsense mutation bypass therapy shows a dramatic multiday response to geneticin.
Yang C; Feng J; Song W; Wang J; Tsai B; Zhang Y; Scaringe WA; Hill KA; Margaritis P; High KA; Sommer SS
Proc Natl Acad Sci U S A; 2007 Sep; 104(39):15394-9. PubMed ID: 17881586
[TBL] [Abstract][Full Text] [Related]
2. Targeting Translation Termination Machinery with Antisense Oligonucleotides for Diseases Caused by Nonsense Mutations.
Huang L; Aghajan M; Quesenberry T; Low A; Murray SF; Monia BP; Guo S
Nucleic Acid Ther; 2019 Aug; 29(4):175-186. PubMed ID: 31070517
[TBL] [Abstract][Full Text] [Related]
3. Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy.
Howard MT; Shirts BH; Petros LM; Flanigan KM; Gesteland RF; Atkins JF
Ann Neurol; 2000 Aug; 48(2):164-9. PubMed ID: 10939566
[TBL] [Abstract][Full Text] [Related]
4. Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system.
Keeling KM; Bedwell DM
J Mol Med (Berl); 2002 Jun; 80(6):367-76. PubMed ID: 12072912
[TBL] [Abstract][Full Text] [Related]
5. Cancer syndromes and therapy by stop-codon readthrough.
Bordeira-Carriço R; Pêgo AP; Santos M; Oliveira C
Trends Mol Med; 2012 Nov; 18(11):667-78. PubMed ID: 23044248
[TBL] [Abstract][Full Text] [Related]
6. No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.
Clancy JP; Rowe SM; Bebok Z; Aitken ML; Gibson R; Zeitlin P; Berclaz P; Moss R; Knowles MR; Oster RA; Mayer-Hamblett N; Ramsey B
Am J Respir Cell Mol Biol; 2007 Jul; 37(1):57-66. PubMed ID: 17347447
[TBL] [Abstract][Full Text] [Related]
7. Aminoglycoside-mediated rescue of a disease-causing nonsense mutation in the V2 vasopressin receptor gene in vitro and in vivo.
Sangkuhl K; Schulz A; Römpler H; Yun J; Wess J; Schöneberg T
Hum Mol Genet; 2004 May; 13(9):893-903. PubMed ID: 14998935
[TBL] [Abstract][Full Text] [Related]
8. Readthrough of dystrophin stop codon mutations induced by aminoglycosides.
Howard MT; Anderson CB; Fass U; Khatri S; Gesteland RF; Atkins JF; Flanigan KM
Ann Neurol; 2004 Mar; 55(3):422-6. PubMed ID: 14991821
[TBL] [Abstract][Full Text] [Related]
9. Treatment of a methylmalonyl-CoA mutase stopcodon mutation.
Buck NE; Wood LR; Hamilton NJ; Bennett MJ; Peters HL
Biochem Biophys Res Commun; 2012 Nov; 427(4):753-7. PubMed ID: 23041189
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the melanocortin-4-receptor nonsense mutation W16X in vitro and in vivo.
Bolze F; Rink N; Brumm H; Kühn R; Mocek S; Schwarz AE; Kless C; Biebermann H; Wurst W; Rozman J; Klingenspor M
Pharmacogenomics J; 2013 Feb; 13(1):80-93. PubMed ID: 21969101
[TBL] [Abstract][Full Text] [Related]
11. The minor gentamicin complex component, X2, is a potent premature stop codon readthrough molecule with therapeutic potential.
Friesen WJ; Johnson B; Sierra J; Zhuo J; Vazirani P; Xue X; Tomizawa Y; Baiazitov R; Morrill C; Ren H; Babu S; Moon YC; Branstrom A; Mollin A; Hedrick J; Sheedy J; Elfring G; Weetall M; Colacino JM; Welch EM; Peltz SW
PLoS One; 2018; 13(10):e0206158. PubMed ID: 30359426
[TBL] [Abstract][Full Text] [Related]
12. Sense from nonsense: therapies for premature stop codon diseases.
Bidou L; Allamand V; Rousset JP; Namy O
Trends Mol Med; 2012 Nov; 18(11):679-88. PubMed ID: 23083810
[TBL] [Abstract][Full Text] [Related]
13. Binary specification of nonsense codons by splicing and cytoplasmic translation.
Thermann R; Neu-Yilik G; Deters A; Frede U; Wehr K; Hagemeier C; Hentze MW; Kulozik AE
EMBO J; 1998 Jun; 17(12):3484-94. PubMed ID: 9628884
[TBL] [Abstract][Full Text] [Related]
14. A novel approach to identify Duchenne muscular dystrophy patients for aminoglycoside antibiotics therapy.
Kimura S; Ito K; Miyagi T; Hiranuma T; Yoshioka K; Ozasa S; Matsukura M; Ikezawa M; Matsuo M; Takeshima Y; Miike T
Brain Dev; 2005 Sep; 27(6):400-5. PubMed ID: 16122626
[TBL] [Abstract][Full Text] [Related]
15. Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment.
Bidou L; Hatin I; Perez N; Allamand V; Panthier JJ; Rousset JP
Gene Ther; 2004 Apr; 11(7):619-27. PubMed ID: 14973546
[TBL] [Abstract][Full Text] [Related]
16. Translational read-through as an alternative approach for ocular gene therapy of retinal dystrophies caused by in-frame nonsense mutations.
Nagel-Wolfrum K; Möller F; Penner I; Wolfrum U
Vis Neurosci; 2014 Sep; 31(4-5):309-16. PubMed ID: 24912600
[TBL] [Abstract][Full Text] [Related]
17. Beneficial read-through of a USH1C nonsense mutation by designed aminoglycoside NB30 in the retina.
Goldmann T; Rebibo-Sabbah A; Overlack N; Nudelman I; Belakhov V; Baasov T; Ben-Yosef T; Wolfrum U; Nagel-Wolfrum K
Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6671-80. PubMed ID: 20671281
[TBL] [Abstract][Full Text] [Related]
18. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin.
Linde L; Boelz S; Nissim-Rafinia M; Oren YS; Wilschanski M; Yaacov Y; Virgilis D; Neu-Yilik G; Kulozik AE; Kerem E; Kerem B
J Clin Invest; 2007 Mar; 117(3):683-92. PubMed ID: 17290305
[TBL] [Abstract][Full Text] [Related]
19. Aminoglycoside suppression of nonsense mutations in severe hemophilia.
James PD; Raut S; Rivard GE; Poon MC; Warner M; McKenna S; Leggo J; Lillicrap D
Blood; 2005 Nov; 106(9):3043-8. PubMed ID: 16051741
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of nonsense-mediated messenger RNA decay in clinical samples facilitates detection of human MSH2 mutations with an in vivo fusion protein assay and conventional techniques.
Andreutti-Zaugg C; Scott RJ; Iggo R
Cancer Res; 1997 Aug; 57(15):3288-93. PubMed ID: 9242462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
